{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:44:27Z","timestamp":1790253867461,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamainternmed.2018.0292","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T12:43:16Z","timestamp":1528116196000},"page":"903","source":"Crossref","is-referenced-by-count":157,"title":["Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function"],"prefix":"10.1001","volume":"178","author":[{"given":"Benjamin","family":"Lazarus","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Division of Nephrology, Monash Medical Centre, Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aozhou","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Sang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Secora","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Chang","sequence":"additional","affiliation":[{"name":"Kidney Health Research Institute, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"ioi180008r1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"ioi180008r2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"ioi180008r3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"ioi180008r4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.","volume":"169","author":"Kooy","year":"2009","journal-title":"Arch Intern Med"},{"issue":"11","key":"ioi180008r5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis.","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"ioi180008r6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/jamainternmed.2014.6936","article-title":"Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications.","volume":"175","author":"Flory","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"15","key":"ioi180008r7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.1976.03260410031019","article-title":"Phenformin and lactic acidosis.","volume":"235","author":"Conlay","year":"1976","journal-title":"JAMA"},{"issue":"6","key":"ioi180008r8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0736-4679(98)00103-6","article-title":"Phenformin and lactic acidosis: a case report and review.","volume":"16","author":"Kwong","year":"1998","journal-title":"J Emerg Med"},{"issue":"2","key":"ioi180008r9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hdi.2014.18.issue-2","article-title":"Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2.","volume":"18","author":"Altun","year":"2014","journal-title":"Hemodial Int"},{"issue":"9","key":"ioi180008r10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-013-0038-6","article-title":"the role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis.","volume":"36","author":"Duong","year":"2013","journal-title":"Drug Saf"},{"key":"ioi180008r11","doi-asserted-by":"publisher","first-page":"b3660","DOI":"10.1136\/bmj.b3660","article-title":"Metformin associated lactic acidosis.","volume":"339","author":"Fitzgerald","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"ioi180008r12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jemermed.2007.11.055","article-title":"Occult metformin toxicity in three patients with profound lactic acidosis.","volume":"40","author":"Perrone","year":"2011","journal-title":"J Emerg Med"},{"key":"ioi180008r13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1752-1947-1-126","article-title":"Metformin-induced lactic acidosis: a case series.","volume":"1","author":"Silvestre","year":"2007","journal-title":"J Med Case Rep"},{"issue":"6","key":"ioi180008r14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/BF02440866","article-title":"Metformin-associated lactic acidosis in Sweden 1977-1991.","volume":"44","author":"Wiholm","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"ioi180008r15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12882-017-0640-4","article-title":"Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy: a systematic review of case reports and case series.","volume":"18","author":"Yeh","year":"2017","journal-title":"BMC Nephrol"},{"issue":"24","key":"ioi180008r16","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review.","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"ioi180008r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney Disease Improving Global Outcomes (KDIGO) Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"ioi180008r20","first-page":"S1","article-title":"Standards of Medical Care in Diabetes - 2016.","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"ioi180008r21","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency.","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"ioi180008r22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2337\/dc15-2534","article-title":"Should restrictions be relaxed for metformin use in chronic kidney disease? yes, they should be relaxed! what\u2019s the fuss?","volume":"39","author":"Bakris","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"ioi180008r23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/dc15-2327","article-title":"Should restrictions be relaxed for metformin use in chronic kidney disease? no, we should never again compromise safety!","volume":"39","author":"Kalantar-Zadeh","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"ioi180008r24","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"ioi180008r25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00592-016-0836-2","article-title":"Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study.","volume":"53","author":"Cucchiari","year":"2016","journal-title":"Acta Diabetol"},{"issue":"4","key":"ioi180008r26","doi-asserted-by":"publisher","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"issue":"8","key":"ioi180008r27","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"},{"issue":"51","key":"ioi180008r28","doi-asserted-by":"publisher","first-page":"e2175","DOI":"10.1097\/MD.0000000000002175","article-title":"Prevalence of metformin use and the associated risk of metabolic acidosis in US diabetic adults with CKD: a national cross-sectional study.","volume":"94","author":"Kuo","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"ioi180008r29","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2337\/dc14-0464","article-title":"Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.","volume":"37","author":"Richy","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"ioi180008r30","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"ioi180008r31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2337\/diacare.22.6.925","article-title":"Incidence of lactic acidosis in metformin users.","volume":"22","author":"Stang","year":"1999","journal-title":"Diabetes Care"},{"issue":"9","key":"ioi180008r33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"ioi180008r34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11096-009-9303-2","article-title":"Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.","volume":"31","author":"Pongwecharak","year":"2009","journal-title":"Pharm World Sci"},{"issue":"12","key":"ioi180008r35","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1463-1326.2010.01295.x","article-title":"Limitations of metformin use in patients with kidney disease: are they warranted?","volume":"12","author":"Vasisht","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"ioi180008r36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0953-6205(02)00131-0","article-title":"Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications.","volume":"13","author":"Rachmani","year":"2002","journal-title":"Eur J Intern Med"},{"issue":"2","key":"ioi180008r37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11606-017-4219-3","article-title":"Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease.","volume":"33","author":"Marcum","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"15","key":"ioi180008r38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes.","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"ioi180008r39","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis.","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"ioi180008r17","author":"Department of Health and Human Services","year":"2016"},{"key":"ioi180008r19","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. Updated May 2017. https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed October 15, 2017."},{"key":"ioi180008r32","unstructured":"National Committee for Quality Assurance. HEDIS and Quality Measurement: HEDIS Measures. 2017. http:\/\/www.ncqa.org\/hedis-quality-measurement\/hedis-measures. Accessed October 15, 2017."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2682516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T13:19:50Z","timestamp":1530537590000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.0292"}},"subtitle":["A Community-Based Cohort Study"],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.0292","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}